Skip left side navigation and go to content

Small Business Catalyst Awards

NHLBI Participation in Small Business Catalyst Awards for Accelerating Innovative Research (R43)


The NHLBI will participate in Small Business Catalyst Awards for Accelerating Innovative Research (R43), which is supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009, Public Law 111-5. This funding opportunity invites grant applications from small business concerns that propose to accelerate innovation through high risk, high reward research and development that has commercial potential and is relevant to the mission of the NIH. The Small Business Catalyst Award is further expected to support entrepreneurs of exceptional creativity, drawn from scientific and technological environments beyond the NIH, who propose pioneering and possibly transformative approaches to addressing major biomedical or behavioral challenges with the potential for downstream commercial development. 

The Small Business Catalyst Award for Accelerating Innovative Research funding opportunity seeks to encourage fresh research perspectives and approaches to serve the mission of the NIH. In particular, applications from small business concerns without a history of NIH Small Business Innovation Research or Small Business Technology Transfer support may receive funding priority.  Solicited are applications for support for projects that have the potential to generate high impact results (e.g., products, processes, or services) and/or innovative research applications, research tools, techniques, devices, inventions, or methodologies. The outcomes of the research supported should have potential to lead to products that will improve public health and create significant value and economic stimulus.

This Funding Opportunity Announcement (FOA) will use the Small Business Innovation Research (SBIR [R43]) grant mechanisms. The Project Director/Principal Investigator will be solely responsible for planning, directing, and executing the proposed project.

The NIH intends to commit as least $5 million in response to this FOA in fiscal year 2010 to fund 20-25 grants, contingent upon the submission of a sufficient number of scientifically meritorious applications. All awards are subject to the availability of funds. Future year amounts will depend on annual appropriations. Total costs (sum of direct costs, Facilities & Administrative costs, and profit/fee) are limited to $200,000 over a one-year period. (Note: Although the budgets for SBIR Phase I projects are generally $100,000 total costs and may be exceeded when justified scientifically, the award amount and project period for this FOA are capped at $200,000 total costs and one year, respectively. Applicants still must provide scientific justification for total costs that exceed $100,000.)  Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size of each award will also vary.

Letters of Intent are due August 3, 2009. Applications are due September 1, 2009.

For general information on the NHLBI’s implementation of the Small Business Catalyst Awards for Accelerating Innovative Research, contact:
Susan Pucie
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health

For Financial or Grants Management questions, contact:
Robert Vinson
Office of Grants Management
National Heart, Lung, and Blood Institute

National Institutes of Health

Last Updated September 4, 2009

Other Important Links

Information from the White House and President Obama

Recovery Information from Health and Human Services

share your recovery act story

  • Did you get Recovery Act funding? Do you have a great story to tell? Let us know about it! E-mail
Twitter iconTwitterExternal link Disclaimer         Facebook iconFacebookimage of external link icon         YouTube iconYouTubeimage of external link icon         Google+ iconGoogle+image of external link icon

Steven Kelsen, M.D.
Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Temple University School of Medicine, Philadelphia, Salim Merali, Ph.D. Associate Professor of Biochemistry; Director of the Proteomics Core, Temple University School of Medicine, Philadelphia, Pennsylvania Karina Davidson, Ph.D.; The Herbert Irving Associate Professor of Medicine and Psychiatry and Director of the Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, New York Picture of Dr.Shuir with two other doctors Photo of Eric Schmidt Image of map; This map highlights a sampling of the NHLBI's support of its scientific community through the American Recovery and Reinvestment Act.